KPTI - Karyopharm Therapeutics GAAP EPS of -$0.30 beats by $0.08 revenue of $38.7M beats by $1.49M

2023-05-04 09:27:10 ET

• Karyopharm Therapeutics press release ( NASDAQ: KPTI ): Q1 GAAP EPS of -$0.30 beats by $0.08 .
• Revenue of $38.7M (-18.8% Y/Y) beats by $1.49M .

• Based on its current operating plans, Karyopharm is updating its guidance for full year 2023:

• Total revenue to be in the range of $145 million to $160 million versus previous guidance of $160 million to $175 million. Total revenue consists of U.S. XPOVIO net product revenue and license, royalty and milestone revenue earned from partners.

• U.S. XPOVIO net product revenue to be in the range of $110 million to $125 million versus previous guidance of $125 million to $140 million, driven by the expectation that the increased use of PAP will continue in 2023, including a cumulative effect from refills.

• Non-GAAP R&D and SG&A expenses, which exclude stock-based compensation expense, to be in the range of $245 million to $260 million versus previous guidance of $260 million to $280 million, driven by accelerated closure of non-priority programs and ongoing disciplined execution.

For further details see: